• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Sonidegib Approved for Basal Cell Carcinoma

Publication
Article
Evidence-Based OncologyAugust 2015
Volume 21
Issue SP12

An oral agent developed by Novartis Pharmaceuticals Corporation has been approved for the treatment of refractory patients with locally advanced basal cell carcinoma (laBCC). Patients who have undergone unsuccessful surgery or radiation treatment, or those who are not eligible for either, can initiate treatment with the sonic hedgehog inhibitor sonidegib (Odomzo). The FDA approval followed results of a randomized, double-blind, multi-center, 2-arm study in patients with laBCC or metastatic BCC. The approval was contingent on a durable objective response rate (ORR).

The phase 2 BOLT trial enrolled 230 patients randomized to receive 800 mg or 200 mg of sonidegib until progression or unacceptable toxicity was observed. Eighty-four percent of trial enrollees had locally advanced disease. Most patients (76%) had received prior therapy for treatment of BCC, and approximately half of these patients (56%) had aggressive histology. The trial results showed a durable ORR of 58% (95% CI, 0.45—0.70) in 66 patients randomized to receive the 200 mg dose of sonidegib, with 3 complete responses and 35 partial responses. While the disease progressed in 7 of the 38 responders, response in 4 of the 7 patients lasted at least 6 months. Patients (128) on the 800-mg arm had an ORR of 44% (95% CI, 0.35–0.53).

The most serious risks of sonidegib are rhabdomyolysis and embryofetal toxicity.

Reference

Sonidegib. FDA website. http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm455865.htm. Accessed July 27, 2015.

Related Videos
Sudipto Mukherjee, MD, PhD, MPH, hematology and medical oncology, Cleveland Clinic
Video 12 - "Key Considerations for Treating Patients Diagnosed With CLL and SLL"
Video 11 - "Optimizing BTKi Treatment Strategies"
Video 13 - "Other Clinical Considerations in Demodex Blepharitis Treatment"
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Video 12 - "Cost-Effective Medication Access in Demodex Blepharitis Management"
Video 10 - "Patient Education Drives BTK Inhibitor Treatment Adherence"
Video 11 - "Understanding Demodex Blepharitis Pathogenesis"
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.